Nav: Home

Statins do not benefit patients with lung cancer, new study shows

February 27, 2017

Cholesterol-lowering drugs used alongside chemotherapy have no effect on treatment outcomes for lung cancer patients, according to a new study.

Recent research into statins has claimed a role for the drugs in preventing cancer development, or prolonging the survival of patients with several common cancers, including lung cancer, and so generated much interest in the medical community. But evidence published by a team from Imperial College London and UCL (University College London) shows that the drugs do not, in fact, benefit lung cancer patients at all.

The research team believe the new evidence is so compelling that existing or new planned trials into the use of statins in cancer treatment should be reconsidered.

The study, funded by Cancer Research UK, is published in the Journal of Clinical Oncology.

Statins work by lowering cholesterol levels in patients and are usually prescribed by doctors to help prevent heart attacks or strokes. A number of small-scale studies published over the past five years have investigated the potential for statins to restrict the growth and survival of cancer cells.

Because cholesterol plays a key role in cell growth messages, it was initially thought that lowering the levels of cholesterol could impair the development and growth of cancer cells. Cholesterol was also believed to delay the recurrence of cancer after treatment has been completed. Collectively these effects were thought to improve the survival of cancer patients.

In the largest randomised trial of statin therapy in cancer patients yet completed, the Imperial team measured the effects of a leading statin, called pravastatin, in patients with small cell lung cancer - a particularly aggressive form of lung cancer where new treatments are desperately needed.

The study included 846 patients from 91 hospitals in the UK and was carried out at the Cancer Research UK & UCL Cancer Trials Centre at the UCL Cancer Institute. Patients were randomly selected to receive either the statin or a placebo alongside their usual chemotherapy treatment, and monitored over two years. The results showed that, although there were no adverse effects from taking statins, there were no advantages either.

"It's becoming increasingly common for patients with increased cholesterol to take statins and many cancer patients will be or have been prescribed these drugs entirely separately from their cancer treatment," explains Professor Michael Seckl from the Faculty of Medicine at Imperial College London, who led the research. "There's no reason for people to stop taking statins to manage their cholesterol, but it's extremely unlikely, for patients with small cell lung cancer, that taking statins will make any difference to their cancer treatment outcome. Because all statins work in a similar way to lower cholesterol, it's relatively unlikely that statins other than Pravastatin would have a different, more beneficial effect."

The Imperial researchers plan to continue their investigations into precisely how statins work at a cellular level, but believe further large-scale trials such as the one just completed may be unnecessary.

"Our results match those of other randomised trials examining different types of cancer, but these were much smaller than our own study, and they have also shown no benefit to using statins in cancer treatment," says senior author Professor Allan Hackshaw, Deputy Director of the Cancer Research UK & UCL Cancer Trials Centre. "Collectively, this evidence seems quite persuasive."

"It is possible that ongoing statin trials of other types of cancers might find a benefit, and so it would be interesting to see their findings when available. However, I think researchers should consider carefully whether to start a new statin trial as part of cancer treatment, without results from further large studies like ours."
-end-


Imperial College London

Related Lung Cancer Articles:

AI helps to fight against lung cancer
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
High levels of estrogen in lung tissue related to lung cancer in postmenopausal women
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.

Related Lung Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...